Loading...
•
Mar 31, 2023
Akebia Q1 2023 Earnings Report
Akebia reported financial results for Q1 2023 and provided business highlights.
Key Takeaways
Akebia Therapeutics reported a total revenue of $40.1 million for Q1 2023, a decrease compared to $61.7 million for Q1 2022. Net loss was $26.2 million, a decrease from $62.4 million in the same quarter of the previous year. The company's cash and cash equivalents totaled $57.0 million as of March 31, 2023.
Vadadustat is now approved in 32 countries following European Commission marketing authorization.
Akebia expects a response to Formal Dispute Resolution from FDA within the next 30 days.
Positive top-line results were released from the vadadustat alternative dosing study.
Auryxia net product revenue was reported as $34.8M for Q1 2023.
Revenue by Segment
Forward Guidance
Akebia affirms 2023 Auryxia net product revenue guidance at $175-$180M.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...